Condition
Leptomeningeal Carcinomatosis
Total Trials
5
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results33% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (2)
P 3 (1)
Trial Status
Unknown2
Terminated2
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02939300Phase 2CompletedPrimary
Ipilimumab and Nivolumab in Leptomeningeal Metastases
NCT00527410Phase 1TerminatedPrimary
A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis
NCT03613181Phase 3UnknownPrimary
ANG1005 in Leptomeningeal Disease From Breast Cancer
NCT02755987Unknown
Expanded Access to ANG1005 for Individual Patients
NCT00830245Phase 2TerminatedPrimary
A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
Showing all 5 trials